Biotech

All Articles

Merck ceases period 3 TIGIT trial in lung cancer cells for impossibility

.Merck &amp Co.'s TIGIT program has gone through another setback. Months after shuttering a period 3...

After a tough year, Exscientia folds up into Recursion

.After a year defined through pipeline cuts, the shift of its own chief executive officer as well as...

Cullinan, after $25M bargain, hands back bispecific to Port

.Cullinan Therapeutics was blown away sufficient with Port BioMed's bispecific immune reactor that i...

A better take a look at Strong Biotech's Tough 15

.In this particular week's episode of "The Top Pipe," we're diving into Tough Biotech's annual Fierc...

Lilly experiences period 2 failing of tau-targeting med

.The confetti is still flying coming from Eli Lilly's gathering commemorating the approval of Alzhei...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our summary of substantial management hirings, shootings ...

Lykos will inquire FDA to reassess its own choice complying with being rejected of MDMA treatment for post-traumatic stress disorder

.Complying with a poor revealing for Lykos Therapeutics' MDMA candidate for trauma at a recent FDA a...

AN 2 halves census, ceases stage 3 trial after records dissatisfy

.AN2 Therapies is actually reconsidering its own business in feedback to lackluster midphase records...

Merck spends $700M for bispecific, snooping autoimmune opening as well as odds to test Amgen in cancer

.Merck &amp Co. is paying $700 million ahead of time to test Amgen in a blood stream cancer cells ma...

Gilead pays for J&ampJ $320M to exit licensing bargain for seladelpar

.With Gilead Sciences about to an FDA decision for its liver illness medication seladelpar, the firm...